Budesonide
| Clinical data | |
|---|---|
| Trade names | Budecort, Rhinocort, Entocort, others |
| Other names | BUD |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608007 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, nasal, tracheal, rectal, inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 10-20% (first pass effect) |
| Protein binding | 85-90% |
| Metabolism | Liver CYP3A4 |
| Elimination half-life | 2.0-3.6 hours |
| Excretion | Urine, feces |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.051.927 |
| Chemical and physical data | |
| Formula | C25H34O6 |
| Molar mass | 430.541 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Budesonide, sold under the brand name Pulmicort, among others, is a steroid medication.[7] It is available as an inhaler, nebulization solution, pill, nasal spray, and rectal foam.[7][8] The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD).[7][9][10] The nasal spray is used for allergic rhinitis and nasal polyps.[8][11] Modified-release pills or capsules and rectal forms may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis, and microscopic colitis.[12][13][14]
Common side effects with the inhaled form include respiratory infections, cough, and headaches.[15] Common side effects with the pills include feeling tired, vomiting, and joint pains.[15] Serious side effects include an increased risk of infection, loss of bone strength, and cataracts.[15] Long-term use of the pill form may cause adrenal insufficiency.[15] Stopping the pills suddenly following long-term use may therefore be dangerous.[15] The inhaled form is generally safe in pregnancy.[15] Budesonide chiefly acts as a glucocorticoid.[15]
Budesonide was initially patented in 1973.[16] Commercial use as an asthma medication began in 1981.[17] It is on the World Health Organization's List of Essential Medicines.[18] Some forms are available as a generic medication.[19][20] In 2022, it was the 177th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[21][22]
- ^ "Regulatory Decision Summary - Uceris". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
- ^ "Tarpeyo- budesonide capsule, delayed release". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
- ^ "Pulmicort Flexhaler- budesonide aerosol, powder". DailyMed. Archived from the original on 19 September 2021. Retrieved 24 December 2021.
- ^ "Eohilia- budesonide suspension". DailyMed. 9 February 2024. Archived from the original on 26 February 2024. Retrieved 26 February 2024.
- ^ "Jorveza EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
- ^ Cite error: The named reference
Kinpeygo EPARwas invoked but never defined (see the help page). - ^ a b c "Budesonide". The American Society of Health-System Pharmacists. Archived from the original on 28 November 2015. Retrieved 2 December 2015.
- ^ a b "Budesonide eent". The American Society of Health-System Pharmacists. Archived from the original on 8 December 2015. Retrieved 2 December 2015.
- ^ De Coster DA, Jones M (2014). "Tailoring of corticosteroids in COPD management". Current Respiratory Care Reports. 3 (3): 121–132. doi:10.1007/s13665-014-0084-2. PMC 4113685. PMID 25089228.
- ^ Christophi GP, Rengarajan A, Ciorba MA (2016). "Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach". Clinical and Experimental Gastroenterology. 9: 125–30. doi:10.2147/CEG.S80237. PMC 4876845. PMID 27274301.
- ^ Rudmik L, Schlosser RJ, Smith TL, Soler ZM (July 2012). "Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis". The Laryngoscope. 122 (7): 1431–7. doi:10.1002/lary.23259. PMID 22410935. S2CID 25637461.
- ^ Silverman J, Otley A (July 2011). "Budesonide in the treatment of inflammatory bowel disease". Expert Review of Clinical Immunology. 7 (4): 419–28. doi:10.1586/eci.11.34. PMID 21790284. S2CID 32892611.
- ^ Pardi DS, Tremaine WJ, Carrasco-Labra A (January 2016). "American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis". Gastroenterology. 150 (1): 247–274.e11. doi:10.1053/j.gastro.2015.11.006. PMID 26584602.
- ^ British national formulary: BNF 58 (58 ed.). British Medical Association. 2009. pp. 56–57. ISBN 9780857111562.
- ^ a b c d e f g "Budesonide". The American Society of Health-System Pharmacists. Archived from the original on 28 November 2015. Retrieved 2 December 2015.
- ^ Domeij B (2000). Pharmaceutical patents in Europe. The Hague: Kluwer Law International. p. 278. ISBN 9789041113481. Archived from the original on 8 December 2015.
- ^ Hamley P (2015). Small Molecule Medicinal Chemistry: Strategies and Technologies. John Wiley & Sons. p. 390. ISBN 9781118771693. Archived from the original on 8 December 2015.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 451. ISBN 9781284057560.
- ^ "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Budesonide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.